Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245

Theme Issue: Highlights from EMVBM 2009

Issue: 2010: 104/3 (Sep) pp. 421–653
Pages: 642-649

Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement

A randomised double-blind dose-response study

G. Raskob (1), A. T. Cohen (2), B. I. Eriksson (3), D. Puskas (4), M. Shi (5), T. Bocanegra (5), J. I. Weitz (6)

(1) College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; (2) King’s College Hospital, London, UK; (3) Sahlgrenska University Hospital; (4) Thunder Bay Regional Hospital, Thunder Bay, Ontario, Canada; (5) Daiichi Sankyo Pharma Development, Edison, New Jersey, USA; (6) McMaster University and the Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada


thromboprophylaxis, venous thromboembolism, Factor Xa inhibitor, anticoagulant therapy, edoxaban


Edoxaban is a new oral direct factor Xa inhibitor. The purpose of this study was to evaluate the efficacy and safety of different doses of edoxaban for the prevention of venous thromboembolism (VTE) in patients undergoing elective total hip replacement. A total of 903 patients were randomised to oral edoxaban 15, 30, 60 or 90 mg once daily or subcutaneous dalteparin once daily (initial dose 2,500 IU, subsequent doses 5,000 IU). Both drugs were begun 6–8 hours postoperatively and continued for 7–10 days, when bilateral venography was performed. The primary efficacy endpoint was the incidence of total VTE, which included proximal and/or distal deep-vein thrombosis (DVT) by venography or symptomatic, objectively confirmed DVT or pulmonary embolism during the treatment period. The primary safety outcome was the incidence of the composite of major and clinically relevant non-major bleeding. All venograms and bleeding events were reviewed by a central independent adjudication committee blinded as to treatment allocation. Of the 903 patients randomised, 776 were evaluable for the primary efficacy analysis. The incidences of VTE were 28.2%, 21.2%, 15.2%, and 10.6% in patients receiving edoxaban 15, 30, 60 and 90 mg, respectively, compared with 43.8% in the dalteparin group (p<0.005 ). There was a statistically significant (p<0.001) dose-response for efficacy across the edoxaban dose groups for total VTE and for major VTE. The incidence of clinically relevant bleeding was low and similar across the groups. Oral edoxaban once daily is effective for preventing VTE after total hip replacement.

You may also be interested in...


Online Supplementary Material

S. Rohatagi (1), J. Mendell (2), H. Kastrissios (3), M. Green (3), M. Shi (2), I. Patel (2), D. E. Salazar (2)

Thromb Haemost 2012 108 5: 887-895

Urs Kistler 1, Inès Kramers-de Quervain 2, Urs Munzinger 3, Nils Kucher4

Thromb Haemost 2008 99 6: 1049-1052

R. M. Bauersachs

Hämostaseologie 2008 28 1: 21-26